<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fibrobiologics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock</link>
<description>Latest news and press releases for Fibrobiologics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fibrobiologics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683567b778dffbe2df0f10a6.webp</url>
<title>Fibrobiologics, Inc. Common Stock</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock</link>
</image>
<item>
<title>FibroBiologics Compliant with All Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-compliant-with-all-nasdaq-listing-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-compliant-with-all-nasdaq-listing-requirements</guid>
<pubDate>Mon, 20 Apr 2026 20:01:00 GMT</pubDate>
<description>HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has confirmed that the Company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq</description>
</item>
<item>
<title>FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-presents-novel-thymus-organoid-platform-to-combat-age-related-immune-decline-at-keystone-symposia-on-aging-and-immunity</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-presents-novel-thymus-organoid-platform-to-combat-age-related-immune-decline-at-keystone-symposia-on-aging-and-immunity</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and</description>
</item>
<item>
<title>FibroBiologics Announces Closing of $3 Million Public Offering</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-closing-of-dollar3-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-closing-of-dollar3-million-public-offering</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company</description>
</item>
<item>
<title>FibroBiologics Announces Pricing of $3 Million Public Offering</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-pricing-of-dollar3-million-public-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-pricing-of-dollar3-million-public-offering-1</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company</description>
</item>
<item>
<title>FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-successful-manufacturing-of-cywc628-drug-product-to-support-upcoming-diabetic-foot-ulcer-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-successful-manufacturing-of-cywc628-drug-product-to-support-upcoming-diabetic-foot-ulcer-clinical-trial</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents</description>
</item>
<item>
<title>FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-reverse-stock-split-to-regain-compliance-with-nasdaqs-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-reverse-stock-split-to-regain-compliance-with-nasdaqs-bid-price-requirement</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a</description>
</item>
<item>
<title>FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-advances-in-burn-treatment-using-proprietary-fibroblast-spheroid-technology-1</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-advances-in-burn-treatment-using-proprietary-fibroblast-spheroid-technology-1</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents</description>
</item>
<item>
<title>FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-completes-site-onboarding-for-phase-12-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers-32</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-completes-site-onboarding-for-phase-12-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers-32</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents</description>
</item>
<item>
<title>FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-inc-announces-issuance-of-us-patent-covering-fibroblast-cell-therapy-for-the-treatment-of-osteoporosis</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-inc-announces-issuance-of-us-patent-covering-fibroblast-cell-therapy-for-the-treatment-of-osteoporosis</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.” The United States Patent and Trademark Office has</description>
</item>
<item>
<title>FibroBiologics to Present at the BIO Investment & Growth Summit</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-to-present-at-the-bio-investment-and-growth-summit</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-to-present-at-the-bio-investment-and-growth-summit</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach</description>
</item>
<item>
<title>FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 24 Feb 2026 21:30:00 GMT</pubDate>
<description>Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; completed payments of outstanding debtHOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using</description>
</item>
<item>
<title>FibroBiologics Granted Extension by Nasdaq to Regain Compliance</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-granted-extension-by-nasdaq-to-regain-compliance</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-granted-extension-by-nasdaq-to-regain-compliance</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it received a favorable determination from a Nasdaq Hearings Panel granting an extension to regain compliance for the continued listing of the Company’</description>
</item>
<item>
<title>FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-chairman-ceo-pete-o-133000396</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-chairman-ceo-pete-o-133000396</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chairman and CEO Pete O’Heeron has been invited to serve as a main stage speaker at the upcoming A4LI’s H-SPAN Summit at Georgetown University. Th</description>
</item>
<item>
<title>FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-issuance-canadian-patent-133000360</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-issuance-canadian-patent-133000360</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Product</description>
</item>
<item>
<title>FibroBiologics to Present at the DealFlow Discovery Conference</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-present-dealflow-discovery-conference-133000281</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-present-dealflow-discovery-conference-133000281</guid>
<pubDate>Tue, 20 Jan 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic</description>
</item>
<item>
<title>FibroBiologics CEO Issues Letter to Shareholders</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-ceo-issues-letter-shareholders-133000108</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-ceo-issues-letter-shareholders-133000108</guid>
<pubDate>Wed, 07 Jan 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders. Fellow Shareholders, Looking back on 2025, I'm reminded of something I've always believed: the best way to predict the future is to i</description>
</item>
<item>
<title>FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-present-9th-annual-bfc-133000136</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-present-9th-annual-bfc-133000136</guid>
<pubDate>Tue, 06 Jan 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Confe</description>
</item>
<item>
<title>FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-positive-preclinical-results-133000802</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-positive-preclinical-results-133000802</guid>
<pubDate>Mon, 05 Jan 2026 13:30:00 GMT</pubDate>
<description>FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced positive preclinical resu</description>
</item>
<item>
<title>FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-files-ind-application-u-133000133</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-files-ind-application-u-133000133</guid>
<pubDate>Wed, 31 Dec 2025 13:30:00 GMT</pubDate>
<description>HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical</description>
</item>
<item>
<title>FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-closing-1-7-210500038</link>
<guid isPermaLink="true">https://6ix.com/company/fibrobiologics-inc-common-stock/news/fibrobiologics-announces-closing-1-7-210500038</guid>
<pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
<description>HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 5,227,275 shares of its c</description>
</item>
</channel>
</rss>